There is something uniquely pathetic about a corporate titan mourning that its customers are becoming healthier. L'Oreal, that venerable bastion of Parisian cosmetic vanity, recently offered an unintended masterclass in boardroom entitlement by grumbling that the proliferation of GLP-1 agonists—the revolutionary weight-loss drugs sweeping through the West—is softening demand for beauty and skincare potions. One can almost hear the pearl-clutching in the C-suite. How dare the sovereign individual spend their marginal dollar on actual metabolic intervention when they could be funneling it into an overpriced jar of hydrocarbon-infused cold cream?
Joseph Schumpeter coined the term "creative destruction" precisely to describe this species of commercial panic. When an entrepreneurial breakthrough arrives, it does not politely ask permission from incumbent monopolists. It arrives like an unseasonal gale, uprooting inefficient capital and reallocating resources toward higher-order consumer utilities. For decades, the global cosmetics industry has operated as an elaborate tollbooth on human insecurity, selling palliative illusions of youth and vitality. Now, biology has finally caught up with chemistry. Consumers have realized that a peptide injection providing genuine physiological regulation offers far greater utility than sixty dollars spent on fermented sea kelp ointment.
Naturally, the managerial class cannot accept that they are simply losing a fair fight in the marketplace. When consumer preference shifts, the modern corporate executive invariably sounds less like a venture capitalist and more like a Soviet commissar whose tractor quota has been disrupted by rain. We are already subjected to the predictable media counter-offensive: breathless warnings about "Ozempic face" and the sudden, urgent need for corrective dermal fillers to repair the supposed tragedy of losing excess adipose tissue. This is pure rent-seeking theater, engineered to manufacture a secondary crisis that the cosmetic industry can then monetize.
Let us be unapologetically clear about the economic reality at play. Consumer sovereignty is not a polite suggestion; it is the fundamental engine of human progress. The individual owns their body, their capital, and their caloric destiny. If an individual calculates that an off-label prescription provides a higher subjective rate of return on their personal well-being than an armada of night creams, that is the end of the debate. L'Oreal holds no property right over the consumer’s vanity, nor does it possess an entitlement to sustained domestic consumption patterns. To argue otherwise is to embrace the fallacy of the broken window, updated for the beauty counter: as if we must all stay metabolically stagnant merely to keep the cosmetic chemists of Clichy gainfully employed.
The historical parallels are as tedious as they are predictable. One recalls the lamplighters’ guilds railing against the incandescent bulb, or the teamsters cursing the internal combustion engine. Whenever genuine innovation threatens an entrenched cartel, the incumbents cry that the natural order has been subverted. The beauty conglomerates have enjoyed monstrous gross margins for half a century because the underlying problem of human metabolic decay remained technologically intractable. That moat is evaporating. A rational consumer does not purchase an inferior substitute when the genuine article becomes affordable, and no amount of French marketing can obfuscate the basic calculus of value.
If the beauty cartel wishes to survive the peptide revolution, it must innovate rather than complain to quarterly earnings calls. Lower prices, develop treatments that complement genuine metabolic health, or pivot toward fields where consumer demand remains robust. But do not expect classical liberals, or any defender of the unhampered market, to shed a tear for the cosmetic balance sheet. The needle has bested the lotion. Raise a glass of water—unsweetened, naturally—to the cold, glorious justice of consumer choice.
Cornelius Bragg